435. Schentag J.J. Sparfloxacin: a review / J.J. Schentag // Clin. Ther. -
2000. - Vol. 22, № 4. - P. 372-387.
436. Schlegel J. Epidemiologie der Tuberculose / J. Schlegel, Ch. Ferlinz,
R.Ferlinz // Internist. - 1995. - Bd. 36, № 10. - S. 951-956.
437. Shah G. Renal magnesium Wasting associfted with terapeutic agents /
G. Shah, M. Kirschenbaum // Miner. Electrolyte Metab. - 1991. - Vol. 17, № 1. -
P 58-64.
438. Shim J.H. Cycloserin-induced lichenoid drug eruption / J.H. Shim, T.Y.
Kim, H.O. Kim, C.W, Kim // Dermatology. - 1995. - Vol. 191, № 2. - P. 142-144.
439. Simpson I.N. Levofloxacin is not associated with significant hepato
biliary adverse reactions / I/N/ Simpson, I. Harding // Intern. J. Antimicrob. - Ag.,
2001. -№ 17. - Suppl. l . - P . 17026.
440. Singh J. Hepatotoxicity due to antituberculosis therapy. Clinical profile
and reintroduction of therapy / J. Singh, P.K. Gard, R.K. Tandon // J. Clin.
Gastroenterol. - 1996. - Vol. 22, № 3. - P. 211-214.
441. Singla R. Efficacy and safety of sparfloxacin in combination with
kanamycin and ethionamide in multidrug-resistant pulmonary tuberculosis
patients: preliminary results / R. Singla, S. Gupta, R. Gupta, V.K. Arora // Int. J.
Tuberc. Lung Dis. - 2001. - Vol. 5, № 6. - P. 559-563.
442. Spear J.F. Relationship between the scaler electrocardiogram and
cellular electrophysiology of the rat heart / J.F. Spear // Rat Electrocardiogram. -
Oxford, 1981.- P . 29-40.
443. Springsklee M. Safety and tolerability profile of moxifloxacin (MFX) /
М/ Springsklee, D. Kubitza // Clin. Microb. Infection. - 1999. - Vol. 5 (Suppl. 3).
- P 140.
444. Stead W.W. Tuberculosis among elderly persons, as observed among
nursing home residets / W.W. Stead // Int. J. Tuberc. Lung Dis. - 1998. - Vol. 2,
№ 9. - Suppl. I . -P . 64-70.
445. Stocker R. Role of oxidative modifications in atherosclerosis / R.
Stocker, J.F Keaney//Physiol. Rev .- 2 0 0 4 . -Vol. 84. - P . 1381-1478.
403
